Psilocybin Treatment Extends Cellular Lifespan and Improves Survival of Aged Mice

Psilocybin treatment extends cellular lifespan and improves survival of aged mice

Psilocybin, the naturally occurring psychedelic compound produced by hallucinogenic mushrooms, has received attention due to considerable clinical evidence for its therapeutic potential to treat various psychiatric and neurodegenerative indications. However, the underlying molecular mechanisms remain enigmatic, and few studies have explored its systemic impacts. We provide the first experimental evidence that psilocin (the active metabolite of p…

Traditional Postpartum Depression Treatments Failed Them. Then They Tried Psychedelics...

New moms are turning to psychedelic mushrooms for postpartum depression relief. Discover the science, the controversy, and what the first U.S. study could mean.

Can psychedelic mushrooms turn back the clock? Study suggests psilocybin preserves telomere length

A compound found in psychedelic mushrooms may have antiaging properties. Researchers at Baylor College of Medicine have found that psilocybin, the active compound in psychedelic mushrooms, may extend both cellular and organismal lifespans.

FDA gives another one of Filament Health’s psilocybin trials green light

Filament Health's new clinical trial on PEX010 aims to address PTSD and alcoholism in veterans and first responders.

FDA Approves Psilocybin Trial for Veterans and First Responders With PTSD and Alcohol Use Disorder

The Marijuana Herald - Marijuana news and information A new clinical trial using a botanical psilocybin drug to treat co-occurring PTSD and alcohol use disorder (AUD) in veterans and first responders has received approval from the U.S. Food and Drug Administration. A new clinical trial using a botanical psilocybin drug to treat co-occurring PTSD and alcohol use disorder (AUD) in veterans and first responders has received approval from the U.S. F…